Showing: 1 - 10 of 27 RESULTS

Florida Cancer Specialists & Research Institute Opens New Location In Lake Worth

FCS Chief Marketing & Sales Officer Shelly Glenn; Medical Assistant Lucille Johnson; Medical Oncologist/Hematologist Shaachi Gupta, MD, MPH; FCS Chief Executive Officer Nathan Walcker; Medical Oncologist/Hematologist Napoleon Santos, DO; Office Manager Anna Gallardo; Medical Oncologist/Hematologist Howard M. Goodman, MD; Regional Director Laura Greene; Medical Oncologist/Hematologist Shachar Peles, MD; Medical Assistant Ashlee Owens; Michele Innocent, APRN; Medical Assistant Paola Council; Medical Oncologist/Hematologist Elizabeth Byron, MD; Kelsey Hagan, PA-C; Regional Physician Liaison Manager Rebecca Appelbaum
FCS Chief Marketing & Sales Officer Shelly Glenn; Medical Assistant Lucille Johnson; Medical Oncologist/Hematologist Shaachi Gupta, MD, MPH; FCS Chief Executive Officer Nathan Walcker; Medical Oncologist/Hematologist Napoleon Santos, DO; Office Manager Anna Gallardo; Medical Oncologist/Hematologist Howard M. Goodman, MD; Regional Director Laura Greene; Medical Oncologist/Hematologist Shachar Peles, MD; Medical Assistant Ashlee Owens; Michele Innocent, APRN; Medical Assistant Paola Council; Medical Oncologist/Hematologist Elizabeth Byron, MD; Kelsey Hagan, PA-C; Regional Physician Liaison Manager Rebecca Appelbaum
FCS Chief Marketing & Sales Officer Shelly Glenn; Medical Assistant Lucille Johnson; Medical Oncologist/Hematologist Shaachi Gupta, MD, MPH; FCS Chief Executive Officer Nathan Walcker; Medical Oncologist/Hematologist Napoleon Santos, DO; Office Manager Anna Gallardo; Medical Oncologist/Hematologist Howard M. Goodman, MD; Regional Director Laura Greene; Medical Oncologist/Hematologist Shachar Peles, MD; Medical Assistant Ashlee Owens; Michele Innocent, APRN; Medical Assistant Paola Council; Medical Oncologist/Hematologist Elizabeth Byron, MD; Kelsey Hagan, PA-C; Regional Physician Liaison Manager Rebecca Appelbaum
Chief Executive Officer Nathan Walcker; President & Managing Physician Lucio Gordan, MD, Medical Oncologist Shachar Peles, MD
Chief Executive Officer Nathan Walcker; President & Managing Physician Lucio Gordan, MD, Medical Oncologist Shachar Peles, MD
Chief Executive Officer Nathan Walcker; President & Managing Physician Lucio Gordan, MD, Medical Oncologist Shachar Peles, MD

Fort Myers, Fla., Oct. 13, 2020 (GLOBE NEWSWIRE) — Fort Myers, Fla., Oct. 12, 2020 — Florida Cancer Specialists & Research Institute (FCS) opened a new facility at 4801 South Congress Ave., Lake Worth, FL 33461 to provide comprehensive treatments and a variety of services to adults with cancer and other diseases. The new location replaces the previous FCS clinic at 5507 South Congress Ave., Suite 130, Atlantis, FL 33462.

The clinic is an expansion of space that includes more than 9,000 square feet, nine private exam rooms and 22 chemotherapy infusion chairs. Patients have access to all existing services and providers, in a comfortable, spacious setting.

“We are thrilled to have the opportunity to provide patients who live in and around Palm Beach County with convenient access to the most advanced treatments close to home,” said FCS CEO Nathan H. Walcker.

“Our new location offers the most advanced treatments for cancer, blood disorders and other diseases in an individualized and compassionate manner,” said FCS President & Managing Physician Dr. Lucio Gordan.

FCS Medical Oncologist Dr. Shachar Peles said, “My colleagues and I are excited to be able to care for our patients in this new facility. It’s a privilege to provide cutting-edge cancer treatments in the comfort of our patients’ local community.”

Four Board-certified medical oncologists Drs. Elizabeth Byron, Shaachi Gupta, Shachar Peles, Napoleon Santos and Board-certified gynecologic oncologist Dr. Howard Goodman, are joined by a team of cancer experts and support staff to provide care in the new Lake Worth office.

###

About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)

Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were

Jennifer Kocour Named Chief Operating Officer of CCT Research as Company Continues U.S. Expansion

An experienced clinical research leader, Kocour will oversee business operations and strategic growth for the CCT Network of Sites

CCT Research, a company offering an innovative approach to conducting clinical trials for the prevention and treatment of debilitating diseases, announced today that Jennifer Kocour has joined the company as its Chief Operating Officer. Kocour brings a wealth of industry experience, having started her career as a Clinical Research Assistant before advancing to roles as a Site Coordinator, Regional Manager, Clinical Team Lead, and Vice President of Operations.

Kocour’s appointment comes as CCT Research continues to rapidly expand its geographic and therapeutic reach since opening its doors in 2017. “I’m excited to join a company that’s dedicated to industry innovation, exceptional patient care, and the growth and development of our staff as we continue to grow as a company,” said Kocour.

CCT Research currently has 17 sites across Arizona, Nebraska, and Utah. The sites are located in physicians’ offices, medical clinics, and senior living communities; and the company is looking to add partner sites in new markets. By embedding its clinical research infrastructure and staff into these facilities, CCT Research provides convenient and comfortable study locations for qualified patients in a variety of therapeutic areas. Recently, the company was selected to partner with several top pharmaceutical companies to conduct trials for a COVID-19 vaccine.

“Strong leadership is key to supporting these critical study efforts and future medical research,” said CJ Anderson, President of CCT Research. “Jennifer is a proven leader, and her diverse background provides an understanding of each individual’s role in conducting a successful clinical trial. We’re happy to have her as the newest member of our executive leadership team.”

About CCT Research

CCT Research is a company offering an innovative approach to conducting clinical trials for the prevention and treatment of debilitating diseases. CCT’s research sites are located within physicians’ offices, medical clinics, and senior living communities to support research in the fields of Neurology, Family Practice, and Dermatology, with plans to include additional therapy areas in the near future. The company’s unique model simplifies the process for trial participants and provides pharmaceutical sponsors with high quality data. For more information, visit cctresearch.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005945/en/

Contacts

CJ Anderson, President
CCT Research
480-702-3501
cjanderson@cctresearch.com

Source Article

How to Gain Research Experience as a Premed Student as Coronavirus Restrictions Continue | Medical School Admissions Doctor

For premed students hoping to gain some research experience before applying to medical school, the ongoing novel coronavirus pandemic poses a challenge to that goal. At a time when so much medical research has taken off, it is hard for students to find places on research teams. Hospitals and other clinical facilities are limiting entry into buildings, as are research labs at universities.

Since research experience can be an important part of a medical school application, figuring out where your application stands in terms of research and whether it makes sense to pursue opportunities at this time is imperative.

As a 2020-2021 applicant to med school, you will likely find yourself in one of three applicant categories.

First are students who already have robust research experience. These students may wish to strengthen their skills further or may have had research projects interrupted by COVID-19, the disease caused by the novel coronavirus.

Second are students who have some research experience, but this research may not be related to science or health care and it may have involved few participation hours.

Finally, some students may have no research experience at all, and they face the prospect of applying to medical school without having had these opportunities.

Students With Robust Research Experience

If you are part of the first category of students, take a deep breath. You have had quality research experiences and have had the chance to hone the research skills that med schools value.

While you can still ask around about furthering your experience, do not worry if you cannot find another research opportunity. Instead, think about other activities that will meaningfully add to your application – like an online class or volunteering to deliver groceries to those at risk for complications from the coronavirus – and pursue those.

Students With Less or No Research Experience

If you are in the second or third groups of students, do not panic. While research is a good thing to have on your med school application, it is not the sole determinant of your admissions worthiness.

For example, I had no research on my med school application and I was admitted to med school. If you find yourself barred from in-person research environments due to the pandemic, reach out to a mentor or faculty member involved in an interesting project and offer to help with literature reviews or data analysis. Both of these types of work are critical to the research process, and they can be done remotely.

If you are unable to secure a research position, think about other means of strengthening your application. And if you are absolutely sure you want to do research prior to enrolling in med school, you always have the option to delay your application to a later cycle. The option to apply to med school will exist whenever you are ready to take it.

Remember that medical schools are sensitive to the disruptions resulting from the coronavirus. While it is important to present the most complete application

Research Paper Matters In Medieval History

A lot of the antibiotics are mixed with anti-allergic medicines like cetirizine Hydrochloride and chlorpheniramine maleate to get good outcome and to ensure our security. Vitamin B12 ( Cyanocobalamine ) is obtained from animal half and used for having good physique well being and widely used in injection form.

Clotrimazole, Beclomethasone Dipropionate, Gentamycin Sulphate, Iodochlorhydroxyquinoline, Chlorocresol, Benzyl Alcohol, Methyl paraben and Propyl barapen are some of the medicines used in the manufacturing of Skin lotions to eliminate pores and skin infections.

Checks which can be carried out on animals vary from them being forced to ingest different household cleaning merchandise after which monitored to see the results and new cosmetics placed on their pores and skin to seek out out if there are any unintended effects that would be dangerous to a human.

Oils used as drugs can be separated into two kinds: fixed and risky. If we can justify that other people feel pain, why is it stated that animals don’t feel ache? The blood lets a health care provider consider a affected person’s well being. With the alarming rate of death because of the dengue virus in this tropical country, the Department of Well being issued an advisory: “By no means belief the medical remedy found on tawa-tawa plant.

Because the scarce rainfall came late of June last yr, the perennial downside on dengue, also known as break-bone fever, lethal illness brought on by the bites low-flying, daytime mosquitoes (Aedes aegypti) claimed lives of mostly Filipino children and a number of other adults.…

Boston research team says it has enrolled a diverse group in Moderna’s coronavirus vaccine study

The hospital is among 90 sites testing to see whether the prospective vaccine made by Moderna is safe and protects people against the coronavirus. The Cambridge biotech’s vaccine is among 11 candidates worldwide that have entered late-stage clinical trials.

“We want our study and enrollment to be representative of the epidemic and the communities disproportionately impacted,” said Baden, who is also one of three leaders of the national study.

Since the study began in the first week of August, Brigham and Women’s has recruited “many hundreds” of participants, he said, adding that he was not free to say exactly how many. Recruitment is continuing and is likely to be completed in “weeks, if not sooner,” Baden said.

Half the participants enrolled nationwide will receive the vaccine candidate, and half will get a placebo, in two injections 28 days apart. Then researchers will watch to see if those who received the vaccine are less likely to get infected. The majority of the Boston participants have received both injections, Baden said.

Some 40 percent of the Boston enrollees are people with health conditions that put them at higher risk of severe infection, and more than 25 percent are elderly, Baden said.

Moderna, like all of the other vaccine makers, wants to make sure it gathers adequate information on the vaccine’s effectiveness among the people most affected by the epidemic, which has disproportionately struck people who are Black and Latino, as well as those with underlying conditions such as heart or lung disease.

Nationwide, the Moderna study has enrolled 28,000 of the 30,000 participants needed to evaluate the vaccine, and 33 percent identify as nonwhite, according to a statement from the company.

The company did not provide a breakdown of which groups are represented in the 33 percent, but Reuters reported earlier this week that 7 percent of enrollees are Black.

Black people comprise 12.3 percent of the nation’s population and 21.1 percent of those who died of COVID-19, according to a recent analysis by National Public Radio. Latino people account for 17.8 percent of the population and 21.1 percent of COVID-19 deaths, NPR found.

Moderna has urged the clinical sites “to further emphasize outreach to diverse populations, even if those efforts impact the speed of enrollment,” its statement said. A spokesperson said these efforts have led to “a modest delay in enrollment completion” but probably will not affect the timing of initial results.

Meanwhile, Moderna’s weekly enrollment data show improvements in recruiting diverse participants; among those who signed up during the week of Sept. 28, 49 percent were Hispanic or Latino people, and 26 percent were Black people.

At Brigham and Women’s, the study team has drawn upon long-established relationships in communities hardest-hit by COVID-19, said Dr. Paulette Chandler, who is leading community education and engagement for the vaccine trial.

“People trust us because they come to us for health care,” she said. The hospital also has a community advisory board established during its decades of work on HIV vaccines. “They served

Pandemic Delays Treatment, Threatening Patients and Research

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

The COVID-19 pandemic has taken a severe toll on patients with retina diseases, according to leading European specialists who took stock and exchanged tips on innovative responses to the crisis at the virtual European Society of Retina Specialists 2020 Congress.

The number of new patients with neovascular age-related macular degeneration decreased by an average of 72% after the onset of the pandemic, said Adnan Tufail, MBBS, MD, from Moorfields Eye Hospital in London, citing findings from a survey he and his colleagues conducted at three treatment centers in the United Kingdom.

A delay in treatment initiation of 3 months could cause an increase of more than 50% in the number of eyes with age-related macular degeneration with 6/60 vision or worse, the survey team estimates, and a 25% decrease in the number of eyes with driving vision over a year.

Significant declines in the number of patients presenting to the hospital for retina treatments were also reported in France and Spain.

“The problem was that patients were afraid to go to the hospital for the injections in their eyes,” said Cesare Mariotti, MD, PhD, from the University of Ancona in Italy.

The overall drop in patients going to the hospital for treatment — roughly 80% across Asia, Europe, and the United States — posed challenges for research, as well as for patients, said Susanne Diehl, PhD, from Novartis in Bavaria, Germany. “Trials will be delayed, approvals will be delayed, and innovation will come to the market delayed.”

Mobile Injection Units

One inventive response to the crisis was to form a mobile intravitreal injection clinic so patients, particularly seniors, could receive treatments in their homes, said Anat Loewenstein, MD, MHA, from Tel Aviv University in Israel.

That service required a lot of infrastructure to set up, and a physician was delegated to review all patient charts to identify those who did not need to be examined before an injection was administered.

It would not be feasible to continue over the long term, but patients loved it, she told Medscape Medical News. “You can’t imagine how people were grateful and happy and were begging us to do that.”

Crews on the mobile units wore masks, face shields, gowns, and gloves, and were tested periodically for COVID-19, Loewenstein reported.

And an entire floor of an office building that wasn’t being used during the pandemic was donated by WeWork, the coworking company, so that Loewenstein and her colleagues could set up a satellite injection clinic, complete with an optical coherence tomography (OCT) machine, for patients not comfortable visiting the hospital.

The strategy in France was to issue a press release and information sheets to reassure patients that they could safely come to the hospital for treatment, said Laurent Kodjikian, MD, PhD, president of the French Society of Ophthalmology.

“Despite that, about 20% to 30% of the patients didn’t come,” said Jean-Francois Korobelnik, MD, from the University Hospital of Bordeaux

How Can Pharma Companies Simplify the Five-Phase Drug Development Process? Infiniti’s Experts Highlight the Need for Product Research Solutions

The increasing competition of the pharmaceutical industry has encouraged companies to invest in innovation and drug development. However, the drug development process is challenging, and without appropriate guidance, developers can face various roadblocks. What is the solution? Infiniti’s product research solutions enable companies to identify, evaluate, and strategize for potential roadblocks through the process. Additionally, our product research experts provide drug developers with crucial insights regarding target customers, regulatory requirements, and competitors’ strategies through the process. This further provides companies with a strategic advantage and enables them to successfully develop and launch a new drug and monitor their success efficiently. To leverage Infiniti’s product research solutions for comprehensive insights regarding the drug development process and an effective strategy, request a free proposal.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005908/en/

Five Phases of the Drug Development Process (Graphic: Business Wire)

With constant technological and pharmaceutical advancements, the pharmaceutical industry is continually becoming more competitive and challenging. Pharmaceutical companies need to focus on innovation and stay ahead of the curve to acquire and maintain market share successfully. Therefore, many pharma companies and researchers have shifted focus on drug development. The drug development process is long drawn and includes multiple phases. It is a five-phase process in the United States and acquiring regulatory approval from the Food and Drug Administration (FDA) is extremely challenging. Therefore, Infiniti’s experts decided to simplify the five-phase drug development process and discuss the value of product research solutions during every stage of the process in their recent article.

Gain comprehensive insights into the five phases of the drug development process and the value of product research solutions by reading the complete article here.

“Although the drug development process becomes easier with more available resources, workforce, and a better understanding of the regulatory requirements, many major pharma companies may still struggle to complete the process without experts’ guidance,” says a pharmaceutical industry expert at Infiniti Research.

Infiniti’s product research experts discussed the following five phases of the drug development process:

  • Discovery and development of a particular compound that elicits a desirable effect on the druggable target for any disease and developing a drug candidate

  • Preclinical research involves testing of the drug candidate on an animal species with similar genetic makeup as humans and gaining an understanding of the dosage and toxicity levels

  • Designing a clinical trial, developing a protocol, and submitting an IND application is part of the third phase of the drug development process

  • The relevant information procured from the preclinical and clinical research is submitted to the FDA for review, and it is either approved, delayed, or referred to an advisory committee for further review

  • The fifth phase involves surveillance of the drug after it has been approved, manufactured, and marketed. This aims to analyze the long-term efficacy and safety of the drug and involves various inspections by FDA representatives

To learn how Infiniti Research helps pharma companies strategize for each phase efficiently, and overcome potential bottlenecks with product research

Allergy Immunotherapies Market – Actionable Research on COVID-19 | Increasing Prevalence of Allergies to Boost the Market Growth

The global allergy immunotherapies market size is poised to grow by USD 626.77 million during 2020-2024, progressing at a CAGR of about 7% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005629/en/

Technavio has announced its latest market research report titled Global Allergy Immunotherapies Market 2020-2024 (Graphic: Business Wire).

The increasing prevalence of allergies is driving the need for allergy immunotherapies. Allergies are regarded as one of the most common ailments, affecting more than 500 million people around the world. The rising incidence of allergy is triggered by factors such as the growing pollution and increased consumption of tobacco products like cigarettes. Moreover, a large portion of people are affected multiple times due to the non-remissive nature of the allergy. The huge unmet need for allergy treatment globally has led to various vendors conducting research on novel therapies, resulting in advances in the field of immunology therapeutics for allergies.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform

Report Highlights:

  • The major allergy immunotherapies market growth came from SCIT segment. It was the largest product segment of the allergy immunotherapies market in 2019, mainly because of the high efficiency for the treatment of various respiratory allergies. Additionally, SCITs are administered in simple and standardized doses, and they result in long-lasting symptom relief. Thus, contributing to the growth of the market in focus.

  • Europe had the largest allergy immunotherapies market share in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. The high prevalence of allergies will significantly influence allergy immunotherapies market growth in this region.

  • The global allergy immunotherapies market is concentrated. Aimmune Therapeutics Inc., ALK-Abelló AS, Allergy Therapeutics Plc, ASIT Biotech SA, DBV Technologies SA, HAL Allergy BV, Jubilant Life Sciences Ltd., Laboratorios LETI SLU, Merck KGaA, and Stallergenes Greer Plc. are some of the major market participants. To help clients improve their market position, this allergy immunotherapies market forecast report provides a detailed analysis of the market leaders.

  • As the business impact of COVID-19 spreads, the global allergy immunotherapies market 2020-2024 is expected to have Neutral and At par growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.

Read the full report here: https://www.technavio.com/report/report/allergy-immunotherapies-market-industry-analysis

Presence of a Strong Pipeline for Allergy Immunotherapy and the Estimated New Approvals will be a Key Market Trend

The strong efficacy and relatively higher safety of allergy immunotherapies combined with a strong prevalence of various allergies create an attractive opportunity for the market players. Hence, several pharmaceutical and biotechnology

Allergy Rhinitis Drugs Market – Actionable Research on COVID-19 | Growing Awareness about Allergic Rhinitis to Boost the Market Growth

The global allergy rhinitis drugs market size is poised to grow by USD 2.4 billion during 2020-2024, progressing at a CAGR of almost 4% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005668/en/

Technavio has announced its latest market research report titled Global Allergy Rhinitis Drugs Market 2020-2024 (Graphic: Business Wire)

This growing awareness about allergic rhinitis has proved critical in helping patients get treated in the early stages of the disease. It also increases the chances of accurate diagnosis by physicians. Globally, the prevalence of allergic rhinitis has increased, and there is an increase in the number of initiatives to increase awareness about the disease.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio’s SUBSCRIPTION platform

Report Highlights:

  • The major allergy rhinitis drugs market growth came from the Antihistamines segment. They are increasingly being used as a first-line approach to prevent or relieve the symptoms of allergic rhinitis. One of the major factors associated with market growth in this segment is the growing number of companies investing in the development of intranasal antihistamines for the treatment of allergic rhinitis.

  • North America was the largest allergy rhinitis drugs market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. The growing prevalence of allergic rhinitis and the availability of a wide range of drugs for the treatment of rhinitis allergy will significantly influence allergy rhinitis drugs market growth in this region.

  • The global allergy rhinitis drugs market is fragmented. Alcon Inc., ALK-Abello AS, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and Stallergenes Greer Ltd. are some of the major market participants. To help clients improve their market position, this allergy rhinitis drugs market forecast report provides a detailed analysis of the market leaders.

  • As the business impact of COVID-19 spreads, the global allergy rhinitis drugs market 2020-2024 is expected to have Neutral and At par growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.

Read the full report here: https://www.technavio.com/report/report/allergy-rhinitis-drugs-market-industry-analysis

Increasing Demand for Over-The-Counter Medicines will be a Key Market Trend

Patients with mild allergies often self-medicate with over-the-counter drugs.These over-the-counter pills that do not require a written prescription from a healthcare professional can be directly purchased from pharmacies. In addition, these over-the-counter drugs have increased the practice of self-medication among individuals. Self-medication also reduces the pressure of medical services. Therefore, patients are inclined toward over-the-counter drugs, which in turn positively impacts the market.

Technavio’s sample reports

COVID-19 ICU Patients Have High Risk of Clots, Research Shows | Health News

By Alan Mozes
HealthDay Reporter

(HealthDay)

TUESDAY, Oct. 6, 2020 (HealthDay News) — Hospitalized COVID-19 patients face an increased risk of developing dangerous blood clots, a new review indicates.

The odds of a clot are highest for the most critically ill patients. Analysis of 66 studies found that 23% of COVID-19 patients in an intensive care unit (ICU) developed a blood clot in the leg, known as a deep vein thrombosis (DVT).

Overall prevalence of a DVT was 14% among ICU and non-ICU COVID-19 patients, and 8% among those with mild-to-moderate disease risk who were not admitted to the ICU.

The “numbers are surprisingly high when compared with other hospitalized patients,” said study author Dr. Cihan Ay.

Of great concern are blood clots in the legs that can break away and travel to the lungs. This is a life-threatening condition known as pulmonary embolism (PE).

Nearly 4% of patients not admitted to the ICU developed a pulmonary embolism. And “we found a very high PE risk of 14% in patients treated at an intensive care unit,” said Ay, an associate professor in hematology and hemostaseology at the Medical University of Vienna in Austria.

According to the American Heart Association, DVT and PE are each a form of venous thromboembolism, or VTE, as both refer to a blood clot that originates in a vein.

VTE is estimated to affect between 300,000 and 600,000 Americans every year, the AHA notes. It is most frequently triggered by surgery, cancer, hospitalization or long-term immobilization.

To examine VTE risk related to COVID-19, Ay and his colleagues analyzed the findings of 66 studies, involving roughly 28,000 COVID-19 patients.

On average, the COVID-19 patients were about 63 years old, and six in 10 were men. About one-fifth had been admitted to an ICU.

None of the studies looked at clotting risk among COVID-19 patients who had not received hospital treatment. So the findings do not speak to DVT or PE risk among such patients, said Ay, although “it seems that the risk of clots is low in patients with a mild clinical course of COVID-19.”

Early in the pandemic, it became clear that blood clot risk seemed elevated in patients with COVID-19 compared to other diseases. To prevent clotting, “physicians worldwide intensified dosing of blood thinners for COVID-19 patients,” Ay said.

This created another potential problem, however, since blood thinners increase the risk of bleeding.

The study authors hope their review will offer clinicians more insight into clotting risk profiles, offering guidance as to which patients truly need preventive clot treatment, Ay said.

As to why COVID-19 might drive up clotting risk in the first place, Ay said experts can only speculate based on available data.

“First, the clinical course in such patients is often severe, which by itself increases the thrombosis [clotting] risk,” he said. “Second, researchers found that COVID-19 interacts with the blood clotting system and the blood vessels, which might explain the increased risk in those patients.”

Dr. Gregg Fonarow is director of the